The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
How do we treat high-risk patients outside of a clinical trial?
Theo de Witte
Rena Buckstein
Yasushi MiyazakiThe MDS Hub Steering Commitee met on May 5, 2022. The recorded discussion was chaired by Theo de Witte, and featured Rena Buckstein, and Yasushi Miyazaki. The topic of this discussion, “How do we treat high-risk patients outside of a clinical trial?”, was identified as an unmet educational need within MDS treatment.
How do we treat high-risk patients outside of a clinical trial?
De Witte discusses approaches to treat high-risk patients, including following the current guidelines in MDS treatment, and potential new drugs that may become approved by the U.S. Food and Drug Administration (FDA). Buckstein discusses the use of hypomethylating agents, and what factors she considers when treating patients with these drugs, such as cytotoxicity. Miyazaki talks about using azacitadine in high-risk patients, following the Japanese guidelines.